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Abstract
Background: Lipoprotein lipase (LPL) has a central role in the catabolism of triglyceride-rich
lipoproteins. The enzyme is anchored to the vascular endothelium through interaction with
heparan sulphate proteoglycans and is displaced from this interaction by heparin. When heparin is
infused, there is a peak of LPL activity accompanied by a reduction in triglycerides (TG) during the
first hour, followed by a decrease in LPL activity to a stable plateau during the remaining session
while TG increase towards and beyond baseline. This suggests that tissue stores of LPL become
depleted. It has been argued that low molecular weight (LMW) heparins cause less disturbance of
the LPL system than conventional heparin does.
Methods: We have followed LPL activity and TG during a dialysis-session with a LMW heparin
(dalteparin) using the same patients and regime as in a previous study with conventional heparin,
i.e. a primed infusion.
Results: The shape of the curve for LPL activity resembled that during the earlier dialyses with
conventional heparin, but the values were lower during dialysis with dalteparin. The area under the
curve for LPL activity during the peak period (0–180 minutes) was only 27% and for the plateau
period (180–240 minutes) it was only 36% of that observed with conventional heparin (p < 0.01).
These remarkably low plasma LPL activities prompted us to re-analyze LPL activity and to measure
LPL mass in frozen samples from our earlier studies. There was excellent correlation between the
new and old values which rules out the possibility of assay variations as a confounding factor. TG
increased from 2.14 mmol/L before, to 2.59 mmol/L after the dialysis (p < 0.01). From 30 minutes
on, the TG values were significantly higher after dalteparin compared to conventional heparin (p <
0.05).
Conclusion: These results indicate that LMW heparins disturb the LPL system as much or more
than conventional heparin does.
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Background
Lipoprotein lipase (LPL) hydrolyses triglycerides (TG) in
circulating lipoproteins [1,2]. This is a necessary first step
in catabolism of the TG-rich lipoproteins as evidenced by
the massive hypertriglyceridemia in patients with genetic
deficiency of the enzyme [3]. Fine-tuned regulation of LPL
activity is an important aspect of energy homeostasis [4].
Patients on chronic hemodialysis (HD) often have
reduced LPL activity and derangements of lipoprotein
profiles [5-7]. During HD, conventional heparin is com-
monly used as anticoagulant and this releases LPL from its
binding sites at the vascular endothelium into the circula-
tion. It has been suggested that repeated heparinisation
may induce release and subsequent degradation of LPL
that exceeds the rate of enzyme synthesis and thereby
causes a depletion of LPL stores [8-11]. In a previous study
we followed the LPL activity and the TG changes during a
dialysis-session using conventional heparin as anticoagu-
lant [12]. There was a peak of LPL activity accompanied by
a reduction in TG during the first hour, followed by a
decrease in LPL activity to a stable plateau during the
remaining session while TG increased towards and
beyond the original baseline. When compared to a group
of healthy control subjects, the peak LPL activity was only
about 50 % in the HD-patients while the plateau activities
were comparable. Our interpretation was that the func-
tional pool of LPL, represented by the initial peak, was
impaired in HD-patients, while the production of lipase
molecules, reflected by the plateau, was only marginally
reduced.
In recent years, conventional heparin has increasingly
been replaced by various low molecular weight (LMW)
heparins. A major argument is the ease of administration
[13,14]. A single injection of a LMW heparin can often
replace a primed infusion of conventional heparin. The
increase in plasma LPL activity is less pronounced after
LMW compared to conventional heparin [15], and it has
been suggested that this causes less disturbance of lipo-
protein metabolism [10] although this conclusion has
been questioned [16]. Direct studies of the lipase-heparin
interaction have shown that a heparin decasaccharide is
enough to fill the heparin-binding grove on the lipase
molecule [17,18]. Decasaccharides fall in the middle or
lower size range in preparations of LMW heparins [19].
Several lines of evidence indicate that also in biological
systems, decasaccharides are sufficiently long to exert full
effect on LPL. Chevreuil et al. found that on a weight basis,
decasaccharides released more LPL from perfused rat
hearts than conventional heparin did [20]. Several groups
have reported that LMW heparins or decasaccharides
release LPL from tissues in vitro or from cultured cells as
efficiently as or even more efficiently than conventional
heparin does. It is therefore unlikely that the lower plasma
LPL activities after LMW heparin are due to less release of
the lipase. More likely, LMW retards clearance of the
lipase by the liver less efficiently than conventional
heparin does. Two studies have directly demonstrated
such a difference in liver perfusion experiments [20,21].
In a recent study we infused a LMW heparin (dalteparin)
for eight hours to healthy volunteers to explore the influ-
ence on LPL activity and TG response [22]. The peak LPL
activity was only about 30%, and the subsequent plateau
activity only about 40%, compared to the activities
observed during a similar infusion with conventional
heparin. A bolus of conventional heparin given when the
LPL activity had levelled off to a plateau brought out
about the same amount of activity irrespective of if the
subjects had been infused with dalteparin or conventional
heparin. We concluded that dalteparin and conventional
heparin had reduced the peripheral stores of LPL to a sim-
ilar extent and that the difference in plasma levels of LPL
activity was due to a more rapid hepatic clearance of the
LPL-dalteparin complex. There was a tendency towards a
more pronounced increase in TG after dalteparin com-
pared to conventional heparin, indicating that lipopro-
tein metabolism might be more, rather than less,
disturbed by the use of LMW heparin. As HD-patients are
increasingly subjected to repeated treatment with LMW
heparin during dialysis we have now followed LPL activity
and TG during a dialysis-session with dalteparin using the
same regime as in our previous study with conventional
heparin, i.e. a primed infusion [12].
Methods
Subjects and protocol
The study design was based on the protocol used in a pre-
vious investigation in which nine HD-patients were stud-
ied during a dialysis-session using conventional heparin
as anticoagulant [12]. The present study, on the same HD-
patients, was performed three months later with a LMW
heparin (dalteparin, Pharmacia, Stockholm, Sweden) as
anticoagulant. In all other respects the dialysis regime, as
well as medication and diet recommendations, was kept
unchanged. The median age was 73 years and the median
BMI was 24.7. The diagnoses were diabetes nephropathy
(BE), chronic pyelonephritis (AJ), nephrosclerosis (HB),
polycystic kidney disease (MK, CH), chronic glomeru-
lonephritis (RH, RS, KL) and in one patient the origin was
unclear (BV, not biopsied). The patients had been on
maintenance hemodialysis for 5–38 months and were
treated with bicarbonate hemodialysis either two (RS,
HB) or three (MK, BE, KL, AJ, RH, CH, BV) times a week,
depending on residual renal function. All dialyses were
performed with hemophan dialysers (GFS+16, GAMBRO,
Lund, Sweden) and Biosol dialysis solution (Pharmalink,
Stockholm, Sweden). A central dialysis catheter was used
as dialysis-access in five of the patients and an arteriov-
enous-fistula/graft in four. The patients were treated withBMC Nephrology 2004, 5:17 http://www.biomedcentral.com/1471-2369/5/17
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antihypertensive drugs (ACE-inhibitors, beta-blockers,
calcium channel inhibitors), diuretics, sodium bicarbo-
nate and phosphate-binding drugs. The diabetic patient
was non-insulin dependent and was treated only by diet
recommendations. One patient (RS), having a rejecting
renal transplant, was treated with low doses of corticoster-
oids and cyclosporine. No one was treated with lipid low-
ering drugs. The experiments were carried out after an
overnight fast, and 48–96 hours had passed since the pre-
vious hemodialysis. A loading dose of 40 IU dalteparin
per kg body weight was given, followed by a continuous
infusion of 1000 IU/hour, in accordance with the manu-
facturer's recommendations. Blood samples were drawn
before start and then regularly at 15, 30, 60, 120, 180 and
240 minutes. According to existing routines, the patients
had a combined breakfast/lunch, containing 25 g fat,
about two hours after the dialysis was started. The ethical
committee approved the study and informed consent was
obtained from all patients prior to participation.
Handling of samples and assay methods
Blood samples for measurement of LPL activity were col-
lected in heparinized tubes. They were immediately
chilled in ice water and centrifuged in a cooling centrifuge
within 15 minutes. The plasma was frozen at -20°C and
then stored at -70°C until analyses. LPL activity was meas-
ured as described [23] using an emulsion containing a
trace amount of [3H]-oleic acid-labelled triolein, 100 mg
soybean TG and 10 mg egg yolk phospholipids per mL,
prepared by Fresenius-Kabi, Uppsala, Sweden. Hepatic
lipase was inhibited by pre-incubation of the plasma sam-
ples with immunoglobulins from a rabbit antiserum to
human hepatic lipase. The assay medium contained a rel-
atively high concentration of heparin, and possible differ-
ences in the heparin concentration or type in the sample
would not affect the activity. All assays were made in trip-
licate and the mean value was used. A standard sample of
human post-heparin plasma was run on each assay day
and the value was used to calibrate for between-assay-var-
iations. LPL protein mass was determined with an
enzyme-linked immunosorbent assay, as previously
described [24], using immunoaffinity-purified chicken
antibodies raised against bovine LPL for capture and the
monoclonal antibody 5D2, also raised against bovine
LPL, for detection (a gift of Dr. J. Brunzell. Seattle, Wash-
ington, USA). Blood samples for lipid determination were
drawn in tubes without anticoagulant, immediately
chilled in ice water, centrifuged and frozen as described
above. Total cholesterol, HDL-cholesterol and TG were
determined by routine methods on a multianalyzer (Vit-
ros 950 IRC; Johnson & Johnson, Clinical Diagnostics Inc,
New York, NY, USA). Baseline LDL-cholesterol levels were
calculated using the Friedewald formula [25]. Antifactor
Xa activity was determined using a chromogenic substrate
(COACUTE®, Chromogenix AB, Mölndal, Sweden).
Statistics
The values are expressed in terms of median and range
and were examined for significant differences by paired
Wilcoxon signed-rank test. Simple linear regression and
the Spearman rank correlation test were used to evaluate
relationships between variables. Two-tailed P values
below 0.05 were considered to be statistically significant.
Results
Baseline data
Table 1 gives baseline data for the HD-patients at the time
of the dialysis-session with dalteparin. There were no sig-
nificant differences compared to the values at the time of
the dialysis with conventional heparin three months ear-
lier [12]. There was no significant difference between the
ultrafiltration rates during the two dialyses.
Table 1: Baseline data for the HD-patients at the time for the dialysis-session with dalteparin. Median values for the dialyses with 
dalteparin (D) and conventional heparin (H), respectively. There were no statistically significant differences between values on the two 
occasions.
HD-patients Gender Age (years) Dbw* (kg) Ultra-
filtration(L)
BMI (kg/m2)T G  
(mmol/L)
Cholesterol 
(mmol/L)
HDL 
(mmol/L)
LDL 
(mmol/L)
MK F 53 71.5 3.0 24.7 3.41 4.5 0.65 2.3
BE F 64 81 2.2 34.2 2.55 5.4 1.24 3.1
KL F 79 76 2.8 28.3 2.14 6.3 0.76 4.5
CH M 55 62.5 3.5 19.5 1.21 3.6 0.99 2.1
BV M 70 77.5 1.3 26.2 1.47 4.6 0.99 2.9
RS M 73 65 2.7 23.3 2.86 7.1 0.96 4.9
RH M 78 62 2.7 21.5 1.09 4.6 1.26 2.9
AJ M 78 73 3.0 26.5 2.84 5.0 0.74 2.9
HB M 90 70 3.0 24.2 1.38 4.4 1.30 2.5
median D 73 71.5 2.8 24.7 2.14 4.6 0.99 2.9
median H 73 70.5 2.2 24.6 1.84 5.6 1.09 3.7
*Dry body weightBMC Nephrology 2004, 5:17 http://www.biomedcentral.com/1471-2369/5/17
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Anticoagulation effect
During the dialysis with dalteparin, the anti-Factor Xa
activity was between 0.52 and 0.87 IU/mL. The target
value recommended by the manufacturer is 0.5–1.0 IU/
mL. Hence, the plasma dalteparin concentration
remained well within the range for effective anticoagula-
tion throughout the dialysis-session.
LPL activity and mass
The LPL-activity rose rapidly when dalteparin was admin-
istered. The highest value was at 15 minutes, median 15
mU/mL (range 9–32). The activity remained high at 30
minutes, but then decreased so that at 120 minutes the
median was only 9 mU/mL (range 5–15) (Fig 1). The
activity then remained essentially unchanged to the end of
the dialysis at 240 minutes (6 mU/mL, range 5–11). The
shape of the curve resembled that during the earlier dialy-
sis with conventional heparin (Fig 1 inset), but the values
were much lower during the dialysis with dalteparin (p <
0.01). The area under the curve (AUC) for LPL activity
during the peak period (0–180 minutes) was 1774 mU/
mL × minutes (range 1116–3001). This is only 27% of the
AUC observed during the earlier study with conventional
heparin [12] (p < 0.01). For the plateau period (180–240
minutes) the AUC was 390 mU/mL × minutes (range
308–618) which is 36% of the corresponding AUC during
the dialysis with conventional heparin (p < 0.01).
The inset in Fig. 1 compares the median values for LPL
activities in the present study to the LPL activities observed
in earlier studies with age and gender matched healthy
subjects given conventional heparin [23], or dalteparin
[22], and with HD patients given conventional heparin
[12]. The values during dalteparin infusion were lower in
both controls and in HD patients. Values in HD patients
were lower than in controls both with dalteparin and with
conventional heparin. Thus, the highest values were for
controls given conventional heparin and the lowest values
were those in the present study with dalteparin in HD
patients. The differences were remarkably large. These
studies have been carried out on separate occasions over
several years, but duplicate samples had been saved fro-
zen. To check the consistency of the values, the duplicate
samples from the 0, 15 and 30 min time points were
thawed and assayed for LPL activity and mass. There was
good agreement between the activities from the earlier
and the repeated assay for all four studies (Fig 2A). Hence,
the large differences between the LPL activities registered
for controls and HD patients and for the two different
heparin preparations were real. As an additional test of the
consistency of the data, we plotted the increase in LPL
activity and LPL mass from basal (before heparin) at the
30 min time points (Fig 2B). The basis for this is that pre-
vious studies have indicated that heparin releases mainly
the active form of the lipase [26]. For regression analysis,
changes in LPL mass of less than 100 ng/mL were
excluded because heparin may release some inactive LPL
[26] and because of the uncertainty in calculating small
differences between pre- and post-heparin mass. The anal-
ysis returned a slope of 0.46 ± 0.05 mU/ng (r = 0.94, p <
0.001), consistent with the expected specific activity of
human LPL (around 0,4 mU/ng under our assay
conditions).
Triglycerides
TG remained essentially unchanged for the first two hours
and then increased. The change from 2.14 mmol/L (range
1.09–3.41) at the start, to 2.59 mmol/L (range 1.49–5.04)
at the end of the dialysis represents a 21 % increase (p <
0.01). Compared to the values during the earlier dialysis
with conventional heparin, there was no statistically sig-
nificant difference at the start of dialysis, but from 30 min-
utes and through the remaining session TG values were
significantly higher during the dialysis with dalteparin (p
< 0.05) (Fig 3). There was no drop in TG at 30 to 60 min
like that found using conventional heparin. There was no
correlation between LPL activity and changes in TG during
any of the dialysis-sessions. To further illustrate the
changes in TG concentrations we have set the baseline
value for each individual to 100% and calculated the
changes from this. Median values for the changes are plot-
ted in Figure 4 which reinforces the conclusion that there
was no significant decrease of TG during the first two
hours during the dialysis with dalteparin, in contrast to
the marked drop observed during dialysis with conven-
tional heparin [12], and during infusion of either conven-
tional heparin [23] or dalteparin in control subjects [22].
Cholesterol
Total cholesterol increased from 4.6 mmol/L (range 3.6–
7.1) at start, to 6.1 mmol/L (range 3.8–8.4) at the end
(32%, p < 0.05). This differs from the earlier dialysis with
conventional heparin, when total cholesterol did not
change from baseline [12].
HDL-cholesterol did not change from baseline. Again, this
differs from the dialysis with conventional heparin when
HDL-cholesterol increased from 1.09 mmol/L (range
0.67–2.06) at start to 1.19 mmol/L (range 0.67–2.31) at
the end (p < 0.05). No correlation was found between LPL
activity and total or HDL-cholesterol changes during any
of the dialysis-sessions.
The median LDL-cholesterol, calculated by the Friedewald
formula, was 2.9 mmol/L (range 2.1–4.9) before the dial-
ysis and increased to 3.75 (2.1–5.6) at 240 min. This cor-
responds to an increase of 29% (p < 0.05).BMC Nephrology 2004, 5:17 http://www.biomedcentral.com/1471-2369/5/17
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Discussion
This study shows the same pattern of plasma LPL activity
in HD patients given dalteparin as observed in previous
studies with control subjects given dalteparin [22] or con-
ventional heparin [23] and in HD patients given conven-
tional heparin [12]. The novel aspect is how remarkably
low the plasma LPL activities were in the HD patients.
This prompted us to re-analyze frozen samples from the
earlier studies to rule out the possibility of assay variations
as a confounding factor. The increase in LPL mass was also
low in the HD patients given dalteparin, and corre-
sponded well to the increase of LPL activity. This further
supports the conclusion that infusion of dalteparin to HD
patients resulted in low levels of LPL in the circulating
blood, compared to what was seen when conventional
heparin was infused [12] or when controls were given
dalteparin or conventional heparin [22,23].
There are several earlier studies that show that administra-
tion of LMW heparin results in lower plasma levels of LPL
Plasma LPL activities during infusion of dalteparin Figure 1
Plasma LPL activities during infusion of dalteparin. The figure shows individual curves for the nine subjects in the 
present study. The inset compares median values from the present study () with those from three earlier studies where the 
same protocol for infusion was used. Control subjects given conventional heparin [23] (● ), control subjects given dalteparin 
[22] (❍ ), HD patients given conventional heparin [12] (■ ).
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than conventional heparin [27-30]. LMW heparin prepa-
rations differ considerably in their molecular
characteristics and caution should be exercised when
extrapolating from one preparation to another. The com-
parisons to our earlier study with conventional heparin
[12] are based on clinically relevant doses during HD, as
recommended from manufacturer's and clinical guide-
lines, not on a molecule-for-molecule basis. In a study
with dalteparin Persson et al. found that the early LPL
activity was only about half as high compared to values
observed after conventional heparin [27,29]. This is simi-
lar to the difference between the AUCs for the early peak
of plasma LPL activity observed here and in an earlier
study with conventional heparin in HD patients [12].
The LPL activities were lower in HD patients than
observed in controls given dalteparin [22]. A similar dif-
ference was earlier found for infusion of conventional
heparin in HD patients [12] compared to controls [23].
One possible explanation is that the depletion of LPL
stores during the dialysis-sessions is not fully restored
between the sessions. Arnadottir et al. have, however,
found that the amount of LPL released by a bolus of
heparin is restored within 24 hours [30]. In rats, it takes
about four hours after a single bolus of LMW heparin
before the LPL stores are replenished [31] and chylomi-
cron catabolism occurs at normal rate [32]. A more likely
explanation is that the kidney dysfunction as such causes
an impairment of the LPL system [33]. Yet another possi-
bility, that has not been explored, is that the kidney itself
makes an important contribution to overall LPL stores.
This is the case in mink, where kidney has a higher LPL
activity than any other tissue, and in mice [34,35].
Administration of heparin causes a temporary derange-
ment of lipoprotein metabolism. In our studies with
Evaluation of the consistency of data from four separate studies by repeated assay of frozen samples Figure 2
Evaluation of the consistency of data from four separate studies by repeated assay of frozen samples. Samples 
had been obtained and treated as described in the methods section and then stored frozen at -70°C in three earlier studies of 
plasma LPL during infusion of conventional heparin or dalteparin in control subjects or in dialysis patients [12,22,23] and the 
present study. Samples from the 0, 15 and 30 min time points were thawed and assayed for LPL activity and mass. Panel A 
shows the LPL activities at 15 and 30 min recorded on the second assay, as a function of the value recorded on the original 
assay. Regression analysis gave a slope indicating that the repeated value was 113 % of the original (r = 0.94, p < 0.0001). Panel 
B shows the increase of LPL activity over the baseline samples plotted against the increase of LPL mass for the 30 min samples. 
For this, values from the second assay were used (LPL mass was not determined in some of the earlier studies). A regression 
analysis, excluding samples for which the increase in LPL mass was less than 100 µg/mL, returned a slope of 0.46 ± 0.05 mU/ng 
LPL (r = 0.94, p < 0.001). Same symbols as in Fig 1.
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control subjects given conventional heparin or dalteparin
the TG concentration decreased after heparin and then
gradually increased again so that at the end of the study
period TG exceeded the baseline level (see inset in Fig 3).
This probably reflects that LPL first becomes more availa-
ble for lipoprotein catabolism as it circulates in blood but
then becomes less available when the lipase is removed
from blood by the liver and the tissues stores become
depleted. This is in accord with observations in animal
experiments. Chevreuil et al. found that the clearance of
injected radioactively labeled chylomicron TG was dra-
matically increased five minutes after rats had been given
conventional heparin or LMW heparin [32]. This was
associated with an increased appearance of label in
plasma FFA, supporting the view that the rate of lipolysis
was increased. In contrast, injection of chylomicrons one
Plasma TG concentrations during infusion of dalteparin Figure 3
Plasma TG concentrations during infusion of dalteparin. The figure shows individual curves for the nine subjects in the 
present study. The inset compares median values from the present study () with those from three earlier studies where the 
same protocol for infusion was used. Control subjects given conventional heparin (● ), control subjects given dalteparin (❍ ), 
HD patients given conventional heparin (■ ). P < 0.05 for dalteparin compared to conventional heparin given to HD patients.
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hour after the heparins resulted in substantially slower
clearance compared to saline-treated controls. Appear-
ance of label in plasma FFA was also decreased, suggesting
that impaired lipolysis was responsible, at least in part, for
the impeded chylomicron clearance.
The decrease of plasma TG was small and statistically not
significant in the HD patients given dalteparin. This may,
at least in part, be explained by the relatively low plasma
LPL activities. In addition, there are reports that in
patients with nephrosis there are inhibitors of LPL in the
circulating blood and that VLDL isolated from such
patients are lipolyzed slowly by LPL [36]. On the other
hand, the rise of TG from two hours was pronounced in
the HD patients. This indicates that the LPL stores were
depleted in these patients even though the plasma LPL
activities were low. This is in accord with results from
animal experiments. Chevreuil et al. injected decasaccha-
rides to rats [20]. This resulted in only a small and short-
lived increase of LPL activity in blood. Nonetheless, the
decasaccharides had apparently removed most of the
functional LPL from peripheral tissues. The LPL activity
that could be released from isolated hearts by single-pass
perfusion with heparin ("functional LPL") was decreased
by 75% one hour after the rats had been injected with
decasaccharides. The catabolism of chylomicron TG by
perfused hearts was delayed to a similar extent. The clear-
ance of labeled chylomicrons injected to rats was mark-
edly delayed from 30 minutes to 2 hours after a
decasaccharide injection. After one hour, the fractional
catabolic rate was only one-third of the control value. All
of this suggests that dalteparin causes a profound deple-
tion of functional LPL even though the plasma levels of
LPL activity are relatively low.
Conclusions
The peak level of LPL in plasma after injection of
dalteparin is less than half of that after conventional
heparin. This was shown here for a group of HD patients,
but a similar difference has earlier been observed for
healthy controls.
The peak level of LPL is lower in HD patients than in con-
trols both after dalteparin and after conventional heparin.
This is probably a consequence of the kidney disease but
the detailed mechanism is not known.
These two effects compound to an almost ten-fold differ-
ence in peak LPL activity comparing the present HD
patients given dalteparin to a group of healthy controls
given conventional heparin. Analysis of LPL activity and
mass in frozen samples from our earlier studies ruled out
the possibility of assay variation as a confounding factor.
Prior in vitro studies of the LPL-heparin interaction, and
animal experiments, indicate that decasaccharides, or
longer heparins, release the enzyme efficiently from its
binding sites at the vascular endothelium. The difference
in plasma levels of LPL is probably due mainly to a differ-
ence in how much the respective heparin retards the
uptake of LPL by the liver.
Immediately after heparin, plasma LPL activity is high and
catabolism of TG-rich lipoproteins is accelerated. This
acceleration was not evident during infusion of dalteparin
to HD-patients. Then follows a period when tissue stores
of LPL are depleted and lipoprotein metabolism is
retarded. This depletion was at least as marked after
dalteparin as after conventional heparin, despite the lower
plasma LPL levels. In the present study, the TG level
increased significantly more after dalteparin than after
conventional heparin.
Changes in plasma TG concentrations during infusion of  dalteparin or conventional heparin to HD patients or  matched controls Figure 4
Changes in plasma TG concentrations during infu-
sion of dalteparin or conventional heparin to HD 
patients or matched controls. For this, the basal TG 
concentration for each individual was set to 100% and the 
concentrations observed at the subsequent time points were 
calculated relative to this. The figure shows median values 
from the present study () and from three earlier studies 
where the same protocol for infusion was used. Control sub-
jects given conventional heparin (● ), control subjects given 
dalteparin (❍ ), HD patients given conventional heparin (■ ).
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Our results indicate that LMW heparins disturb the LPL
system as much or more than conventional heparin does.
Abbreviations
AUC – area under the curve; HD – hemodialysis; HDL –
high density lipoprotein; LMW heparin – low molecular
weight heparin; LPL – lipoprotein lipase; TG – triglycer-
ides; VLDL – very low density lipoprotein
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